Navigation Links
Anpac Bio-Medical Presents 'Cancer Differentiation Analysis' Research at Nobel Laureate Cancer Research Summit

SACRAMENTO, Calif., May 13, 2015 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu this week presented what event organizers published as, "very promising" and "breakthrough" early cancer detection technology research results at the "2015 Nobel Prize Laureate Summit on Biomedical Science: Frontiers in Cancer Research" (NPLS) in Tianjin, China.

The NPLS was the first meeting of five Nobel Laureate Prize winners and the 20 top cancer researchers in the world, gathering for an unprecedented exchange of research results and advances related to cancer identification, diagnosis, and treatment.

An accomplished inventor with over 200 patent applications (100 related to leading-edge cancer research/diagnostics), as well as a member of the American Society of Clinical Oncologists (ASCO), Dr. Yu was welcomed by Summit organizers to share Anpac's innovative "Cancer Differentiation Analysis" (CDA) technology results; revealing Anpac's CDA effectively reinventing cancer screening and early cancer detection, through simple, standard, non-invasive blood tests – known as "Blood Biopsies"-- and Anpac CDA medical devices.

Anpac's CDA technology essentially executes for patients and doctors "Blood Biopsies", which research reveals quickly, efficiently, and dramatically improves cancer detection sensitivity and specificity-- without producing any side effects in patients.

In other words, Anpac's CDA diagnostics can identify threatening cancer cells – and the type of cancer cells (or where they are located in the body) – often before those cells become or grow into Stage 1+ tumors (or potentially even forming into tumors in the first place).

Comprehensive research validity data from nearly 20,000 cases indicate Anpac's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 70%-85% for over ten different types of cancer, with the ability of early stage detection for most of them.

NPLS organizers list the outline of Dr. Yu's research in the Nobel Prize Laureate Summit Research Paper Compilation as: A New Generation Cancer Diagnostic Technology with High Sensitivity and Specificity, Fast Detection Speed, No Side Effects, Ability for Early Diagnosis, and Cost Efficiency.  And it concludes the research summary with, "CDA technology is a game-changing, effective approach in detecting a number of cancer sites at an early stage with the potential to resolve several existing issues in the field of cancer diagnostics."

For further information:; or Anpac Bio-Medical Science Company, Ltd.:

Photo -

Photo -


SOURCE Anpac Bio-Medical Science Company, Ltd.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee
2. Paradigm CEO Dr. Robert Penny Presents Keynote Address at 2015 ISBER Conference
3. Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors
4. DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083s Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
5. Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform
6. Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015
7. Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th
8. Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
9. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
10. Dr. Sanford Silverman Presents Correlation of Genetics and Pain Management on Behalf of Proove Biosciences, Inc.
11. ASBM Presents European Physicians Survey at Spanish Ministry of Health
Post Your Comments:
(Date:1/7/2020)... Mass. (PRWEB) , ... January 06, 2020 , ... ... for a Digital World at The Fletcher School at Tufts University, is pleased ... Sloan Foundation. The grant will be administered by Tufts University, and will help ...
(Date:12/31/2019)... N.J. (PRWEB) , ... December 31, 2019 , ... At ... the conference that will be broadly focused on 3D cell culture , ... its NASH 3D cell culture assays for assessing steatosis , inflammation and ...
(Date:12/23/2019)... ... December 23, 2019 , ... Leak Detection Associates, the ... and Medical Device Industries, is excited to announce that it will be a ... Container Closure Integrity Testing Basic Training Course . Held in conjunction with PDA ...
(Date:12/14/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... December 12, ... ... world’s premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, ... major product launch of 2019. The new LDA LT80 (LOW TEMPERATURE -80C) helium ...
Breaking Biology Technology:
(Date:12/4/2019)... MELVILLE, N.Y. (PRWEB) , ... December 04, 2019 ... ... growing aesthetics companies today, has launched Subnovii Advanced Plasma Technology for ... their breakthrough portfolio, Subnovii is the only plasma to employ LF technology – ...
(Date:11/27/2019)... ... November 26, 2019 , ... Smile Glen ... IL practice for Invisalign® treatment. Invisalign orthodontics uses a series of ... misaligned bite, also known as malocclusion, present both functional and cosmetic concerns. Functionally, ...
(Date:11/22/2019)... N.Y. (PRWEB) , ... November 21, 2019 , ... ... developed at Roswell Park Comprehensive Cancer Center have announced a major step forward ... Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park ...
Breaking Biology News(10 mins):